Agenda

- 1. Overview of variables
 - Demographics
 - Tumor characteristics
 - Treatment
 - Follow-up and dates
 - County attributes
- 2. Cancer type recodes
- 3. Cancer type specific variables
- 4. Staging definitions
 - Caution when using over time



Cancer type specific variables






Background on Collaborative Staging (CS)

- A data collection system that uses a single set of data elements based on extent of disease and clinically relevant factors
 - Site specific factors (SSFs)
- It was designed to meet the needs of multiple staging systems and eliminate duplicate data collection by cancer registrars reporting to different types of registries (facility- vs population-based)
 - SEER summary stage 2000 and 1977, SEER historic stage, AJCC staging
- The CS system was introduced first in 2004 (CSv1) and updated in 2010 (CSv2) in conjunction with the release of the 7th edition of the AJCC Cancer Staging Manual
 - along with a section on prognostic factors for which collection is recommended









Background on Collaborative Staging (Cont.)

- SSFs in CS include numerous prognostic/predictive factors & biomarkers; can be used to evaluate outcome
- Much resources have been spent on the collection of CSv2 (because more factors were incorporated for collection)
- Not all of the SSFs are released on the SEER research file
 - no longer required
 - Being evaluated for completeness
 - After review was found to be of NOT as high quality as other SEER variables in the research database)



Define cancer schemas for analyzing SSFs





Define Cancer Schema vs. Site Recode

- Over the years there have been multiple standards for grouping similar cancer types by primary site and histology. Two major classifications:
 - SEER Site Recode: Groupings consistent with historic definitions used for collecting disease metrics in earlier time periods included in SEER data
 - Schemas: Groupings used in CS to dictate the appropriate staging and sitespecific factors collected. Different versions of CS defined groups differently



Define Cancer Schema vs. Site recode Cont.

- How different are the cancer schemas from site recodes?
 - It depends. For example, breast cancer no change in schema vs. site recode
 - Whereas colon cancer have more changes in schema compared to site recode
 - Any analyses using CS SSFs should use CS schema to define the cohort (not the SEER site recode variable)



SEER Site Recode ICD-O-3/WHO 2008 Definition

Site Group	ICD-O-3 Site	ICD-O-3 Histology (Type)	Recode	
Colon excluding Rectum				
Cecum	C180		21041	
Appendix	C181		21042	
Ascending Colon	C182	excluding 9050-9055, 9140, 9590-9992	21043	
Hepatic Flexure	C183		21044	
Transverse Colon	C184		21045	
Splenic Flexure	C185		21046	
Descending Colon	C186		21047	
Sigmoid Colon	C187		21048	
Large Intestine, NOS	C188-C189, C260		21049	
Rectum and Rectosigmoid Junction				
Rectosigmoid Junction	C199		21051	
Rectum	C209		21052	

https://seer.cancer.gov/siterecode/icdo3_dwhoheme/





Colon and Rectum Cancer Site recode vs. Schema, SEER-21 2018

SEER Site Recode	Schema	Count
Colon and Rectum	Appendix	1,183
Colon and Rectum	Colon and Rectum	45,910
Colon and Rectum	Digestive Other	33
Colon and Rectum	NET Appendix	1,008
Colon and Rectum	NET Colon and Rectum	1,689
	Soft Tissues Abdomen and Thoracic (excluding Heart, Mediastinum, Pleura)	39
Colon and Rectum	GIST	56
Colon and Rectum	Soft Tissue Other (or Unusual Sites and Histology)	3





Data Dictionary in SEER*Stat

Dictionary Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000-2018) Age at Diagnosis Close (+) \sim Race, Sex, Year Dx, Registry, County ŧ Site and Morphology Help ۰ Stage - Summary/Historic ÷ Stage - 8th edition ۰ Create. Stage - 7th edition + Stage - 6th edition ÷ E dit... Stage - Other ۰ Therapy ۰ Delete. Site-Specific Data Item Recodes ÷ Extent of Disease (Ŧ) Extent of Disease - Historic ÷ Merge... Cause of Death (COD) and Follow-up + Multiple Primary Fields ÷ Site and Morphology - Historic ÷ Import... Race and Age (case data only) (F) Geographic Locations Export... ۰ (+) Dates Categories... Site Specific Sequence Numbers + Other (+) County attributes ACS - 2015-2019 Ē County attributes ΔCS - 2014-2018 中 Find... <



Site Recode vs Schema

	Bow Column
	Column
	Form
v	End.
	v

Cancer Site-specific Data Items Collection Now

• The SSFs under CS system was continued to be collected until 2017 but no longer available for the latest years of diagnosed cases

 Beginning with cases diagnosed in 2018+, site-specific data items (SSDIs) are available for 2018+ cases: <u>https://seer.cancer.gov/seerstat/variables/seer/ssdi/</u>

• Some of the SSDIs are available in the latest SEER research file



Site-specific Data Items (SSDI)

Variable Name	Description	Cancer Schemas(s)
AFP Post-Orchiectomy Lab Value Recode (2010+)	Created from NAACCR Item #3805 & CS site- specific factor 12 (NAACCR #2866). Coded for cases coded as Testis in BOTH TNM 7/CS v0204+ Schema & EOD Schema Id.	Testis
	Formats: +	
AFP Pretreatment Interpretation Recode (2010+)	Created from NAACCR Item #3809 & CS site- specific factor 1 (NAACCR #2880). Coded for cases coded as Liver in BOTH TNM 7/CS v0204+ Schema & EOD Schema Id.	Liver E
	Formats: +	
3 Symptoms Recode (2010+)	Created from NAACCR Item #3812 & CS site- specific factor 2 (NAACCR #2890). Coded for cases coded as Lymphoma or Lymphoma-CLL/SLL in	Lymphoma, Lymphoma- CLL/SLL

https://seer.cancer.gov/seerstat/variables/seer/ssdi/

Site Specific data items

B Site Specific Data Item Recodes	∧ <u>Page</u>
AFP Post-Dirchiectomy Lab Value Recode (2010+)	
AFP Pretreatment Interpretation Recode (2010+)	Bow
- B Symptoms Recode (2010+)	C.L.
Breslow Thickness Recode (2010+)	Golumn
 CA-125 Pietrealment Interpretation Recode (2010+) 	
CEA Pretreatment Interpretation Recode (2010+)	
Fibrosis Score Recode (2010+)	
 — Gestational Trophoblastic Prognostic Scoring Index Recode (2010+) 	
Gleason Patterns Clinical Recode (2010+)	
Gleason Paterns Pathological Recode (2010+)	
— Gleason Score Clinical Recode (2010+)	
— Gleason Score Pathological Recode (2010+)	
— hCG Post-Orchiectomy Range Recode (2010+)	
— 1 Invasion Beyond Capsule Recode (2010+)	v <u>F</u> ind



Breast cancer SSFs





Breast cancer SSFs

- A total of 24 SSFs were collected in the SEER registries
- Six of them collected since CSv1 (SSF 1-6) for cases diagnosed in 2004+; remining SSFs collected for cases diagnosed beginning of 2010 and all the way up to 2017
- Can be grouped into 4 main categories:
- Stage-related (N=3)
- Prognosis/prediction (N=2)
- Treatment/Prognosis (N=3)
- Biomarkers/treatment (N=10)



Breast Cancer SSFs

Variables	SSF Description
SSF1	Estrogen Receptor (ER) Assay
SSF2	Progesterone Receptor (PR) Assay
SSF3	Number of Positive Ipsilateral Axillary Lymph Nodes
SSF4	Immunohistochemistry (IHC) of Regional Lymph Nodes
SSF5	Molecular Studies of Regional Lymph Nodes
SSF6	Size of Tumor—Invasive Component


Note: CS version 1 began for cases diagnosed in 2004+; CS version 2 was required for 2010 +cases but may be coded for earlier years of diagnosis.






Variables	SSF Description
SSF7	Nottingham or Bloom-Richardson (BR) Score/Grade
SSF8	HER2: IHC Laboratory Value
SSF9	HER2: IHC Test Interpretation
SSF10	HER2: FISH Laboratory Value
SSF 11	HER2: FISH Test Interpretation
SSF 12	HER2: CISH Laboratory Value
SSF 13	HER2: CISH Test Interpretation
SSF 14	HER2: Result of Other or Unknown Test
SSF 15	HER2: Summary Result of Testing ^c
SSF 16	Combinations of ER, PR, and HER2 Results
SSF 17	Circulating Tumor Cells (CTC) and Method of Detection
SSF 18	Disseminated Tumor Cells (DTC) and Method of Detection
SSF 19	Assessment of Positive Ipsilateral Axillary Lymph Nodes
SSF 20	Assessment of Positive Distant Metastases
SSF 21	Response to Neoadjuvant Therapy
SSF 22	Multigene Signature Method
SSF 23	Multigene Signature Results
SSF 24	Paget Disease

% of Cases with Known Value after Filter by Site-Specific Factor Breast Cancer, SEER Combined, 2010







% of Cases with Known Value after Filter by Site-Specific Factor

CS Site specific factors

😑 Extent of Disease	~	Page
EOD Primary Tumor (2018+)		Bow
- 1 EOD Regional Nodes (2018+) - 1 EOD Mets (2018+)	-	
Tumor Size Summay (2016+)		Colum
Regional nodes examined (1988+)		
Regional nodes positive (1988+)		
SEER Combined Mets at DK-bone (2010-)		
SEER Combined Mets at DiVibrain (2010+) SEER Combined Mets at DiVibrai (2010+)		
SEER Combined Mets at DK-lung (2010+)		
Mets at DKOpistant LN (2016+)		
- Nets at DK-Other (2016+)		
Breat Subtype (2010+)		End.
ER Status Recode Breast Cancer (1990+)	v _	Eur.
		A ICAPS
ble Valables		m it area
ER Status Recode Breast Cancer (1990+)	~	Eage
PR Status Recode Breast Cancer (1990+)	-	Row
Derived HER2 Recode (2010+) Lymph-vascular Invasion (2004+ varying by schema)	-	
- C Channer size (2004-2015)		Column
- CS extension (2004-2015)		
CS [mph nodes [2004-2015]		
- CS mets at ds (2004-2015)		
C S Mets Eval (2004/2015)		
CS site-specific factor 1 (2004-2017 varying by schema)		
 CS site specific factor 2 (2004-2017 varying by schema) 		
 C5 site-specific factor 3 (2004-2017 varying by schema) 	- T	End.
- CS site-specific factor 4 (2004-2017 varying by schemal	•	Exa-
		A ICAPS
		O Love 2 1



Breast cancer CS SSFs paper

Overview of Breast Cancer Collaborative Stage Data Items—Their Definitions, Quality, Usage, and Clinical Implications: A Review of SEER Data for 2004-2010

Nadia Howlader, MS¹; Vivien W. Chen, PhD²; Lynn A. G. Ries, MS^{1,3}; Michelle M. Loch, MD⁴; Richard Lee, BS⁵; Carol DeSantis, MPH⁶; Chun Chieh Lin, PhD, MBA⁶; Jennifer Ruhl, MSHCA¹; and Kathleen A. Cronin, PhD, MPH¹





Useful links for SSFs

• SSDIs that are available released in SEER research file (by cancer schema and year of diagnosis)

https://seer.cancer.gov/seerstat/variables/seer/ssdi/

SEER monograph

https://seer.cancer.gov/publications/collabstaging/

• Analysis of SSFs –nitty gritty

https://surveillance.cancer.gov/reports/tech2015.01.pdf

• SEER staging information

https://staging.seer.cancer.gov/



Breast cancer Molecular Subtype Analysis in SEER*Stat



Data	Selected Database		
Statistic Selection	Order Location Database ID Link ID	5 ssp://seerstat.imsweb.com:2040 2137 2193	
Table Output	Database Name Linked To Linked By Population Variables	Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000-2018) County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties State-county, Year of diagnosis Race recode (W, B, Al, API)	*
	Change Selected I Suggested Citation	Database	
	Limited-Field Data, 21 F	ogy, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, ational Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020	
	Сору		
Ready			




Data	Statistic
Statistic	 Frequencies Trends
Selection Table	Percentages
Output	 None Row Column
	Parameters
	P-Values: 0.05 Edit
	Trend Variable: Year of diagnosis
	PC End Points
	One Year Two-Year Average
	APC Calculation O Weighted Least Squares Non-Weighted Least Squares
	Show Confidence Interval Delay Adjust Delay Factor:



Data	Select Only	View Statements
Data	Malignant Behavior	
Statistic	Known Age	
Selection	Male or Female Sex	
Table	Cases in Research Database	
Output	Selection Statement	
Output	{Race, Sex, Year Dx.Year of diagnosis} = '2010','2011','2012','2013','2014','2015','2016','2017','2018' AND {Site and Morphology.EOD Schema ID Recode (2010+}) = 'Breast' AND {Race, Sex, Year Dx.Sex} = 'Female' Edit Copy Clear Select only the first Matching Record for each Person Person Selection Use Person Selection	








Data	Title (Up to 5 Lines)					
Statistic Selection	SEER 21, 2010-2018 Malignant Female Breast Cancer by SubType					
Table	Options					
Output	Number of Decimal Places for Trends/Percentages:	0.1	~	Set Default		
	Hide Statistics When Fewer Than	25 Case	5			
	Include Individual Year Counts					



Matrix		Count	Column %	Cum %
Settings	HR+/HER2+ (Luminal B)	75,905	9.7%	9.7%
	HR-/HER2+ (HER2 enriched)	32,205	4.1%	13.7%
Graph	HR+/HER2- (Luminal A)	533,629	67.9%	81.6%
	HR-/HER2- (Triple Negative)	79,478	10.1%	91.7%
	Unknown	65,237	8.3%	100.0%
	Recode not available	0	0.0%	100.0%
	Total	786,454	100.0%	100.0%











www.cancer.gov/espanol

www.cancer.gov